Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Stock Information for Kalaris Therapeu

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kalaris Therapeu

Kalaris Appoints Laurie Keating to Board of Directors
Kalaris to Present at Clinical Trials at the Summit 2026
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.